An In Silico Knockout Model for Gastrointestinal Absorption Using a Systems Pharmacology Approach - Development and Application for Ketones.
Gastrointestinal absorption and disposition of ketones is complex. Recent work describing the pharmacokinetics (PK) of d-β-hydroxybutyrate (BHB) following oral ingestion of a ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate) found multiple input sites, nonlinear disposition and feedback on endogenous production. In the current work, a human systems pharmacology model for gastrointestinal absorption and subsequent disposition of small molecules (monocarboxylic acids with molecular weight < 200 Da) was developed with an application to a ketone monoester. The systems model was developed by collating the information from the literature and knowledge gained from empirical population modelling of the clinical data. In silico knockout variants of this systems model were used to explore the mechanism of gastrointestinal absorption of ketones. The knockouts included active absorption across different regions in the gut and also a passive diffusion knockout, giving 10 gut knockouts in total. Exploration of knockout variants has suggested that there are at least three distinct regions in the gut that contribute to absorption of ketones. Passive diffusion predominates in the proximal gut and active processes contribute to the absorption of ketones in the distal gut. Low doses are predominantly absorbed from the proximal gut by passive diffusion whereas high doses are absorbed across all sites in the gut. This work has provided mechanistic insight into the absorption process of ketones, in the form of unique in silico knockouts that have potential for application with other therapeutics. Future studies on absorption process of ketones are suggested to substantiate findings in this study.
School of Pharmacy, University of Otago, Dunedin, New Zealand.
Vittal
V
Shivva
School of Pharmacy, University of Otago, Dunedin, New Zealand.
Ian G
IG
Tucker
School of Pharmacy, University of Otago, Dunedin, New Zealand.
Stephen B
SB
Duffull
Arch Intern Med. 1977 Apr;137(4):495-501
403870
J Pharm Sci. 1972 Sep;61(9):1361-5
5068940
Diabetes Metab Res Rev. 1999 Nov-Dec;15(6):412-26
10634967
Pediatrics. 2007 Mar;119(3):535-43
17332207
Biochem J. 1999 Oct 15;343 Pt 2:281-99
10510291
Adv Drug Deliv Rev. 2001 Oct 1;50 Suppl 1:S41-67
11576695
Biopharm Drug Dispos. 1995 Jul;16(5):351-80
8527686
Drug Metab Dispos. 2006 Apr;34(4):690-5
16434544
Pharm Res. 2006 Aug;23(8):1675-86
16841194
Biochem J. 1994 Dec 15;304 ( Pt 3):751-60
7818477
Biochem J. 1999 Aug 1;341 ( Pt 3):529-35
10417314
J Clin Invest. 1969 Mar;48(3):574-83
5773093
Xenobiotica. 2008 Jul;38(7-8):1072-106
18668440
Pharm Res. 1993 Jul;10(7):1093-5
8378254
Methods Enzymol. 1981;77:333-44
7329311
J Neurochem. 2006 Jul;98 (1):279-88
16805814
AAPS J. 2008;10(1):193-9
18446519
CPT Pharmacometrics Syst Pharmacol. 2014 Oct 22;3:e142
25338195
CPT Pharmacometrics Syst Pharmacol. 2014 Feb 19;3:e101
24552986
IUBMB Life. 2012 Jan;64(1):1-9
22131303
AAPS J. 2016 May;18(3):678-88
26893218
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2031-5
9050899
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5440-4
10805800
Regul Toxicol Pharmacol. 2012 Aug;63(3):401-8
22561291
Metabolism. 1979 Jan;28(1):41-50
759825
Eur J Pharm Sci. 2004 Mar;21(4):429-41
14998573
IUBMB Life. 2012 Feb;64(2):109-19
22162139
Curr Drug Metab. 2010 Nov;11(9):716-29
21189140
Drug Metab Dispos. 2011 Jul;39(7):1196-202
21447733
Am J Physiol Cell Physiol. 2005 Oct;289(4):C846-52
15901598
Am J Physiol. 1995 Apr;268(4 Pt 1):E660-7
7733265
Gastroenterology. 1989 Mar;96(3):736-49
2914637
Toxicon. 2008 Dec 1;52(7):769-80
18831981
J Pharm Pharmacol. 1997 Apr;49(4):450-7
9232547
J Physiol. 2000 Dec 1;529 Pt 2:285-93
11101640
Biol Pharm Bull. 2003 Oct;26(10):1442-7
14519952
Scand J Gastroenterol. 1991 Dec;26(12 ):1263-71
1763296
IUBMB Life. 2001 Apr;51(4):241-7
11569918
J Biol Chem. 1996 Jan 12;271(2):861-8
8557697